Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

AbbVie Inc (NYSE:ABBV)

72.39
Delayed Data
As of 4:00pm ET
 -0.35 / -0.48%
Today’s Change
55.06
Today|||52-Week Range
73.67
+15.60%
Year-to-Date
Bristol-Myers Reports Data on Immuno-Oncology Drug Empliciti
10:39am / Zacks.com - Paid Partner Content
J&J-AbbVie's Imbruvica Positive in Follow-up Lymphoma Study
Jun 20 / Zacks.com - Paid Partner Content
Gilead's (GILD) HCV Drug Application Accepted in the EU
10:39am / Zacks.com - Paid Partner Content
Global pharma sales forecasts cut amid pricing pressures
Jun 20 / FT.com - Paid Partner Content
AbbVie's HCV Combo Drug Gets Positive CHMP Opinion in EU
10:30am / Zacks.com - Paid Partner Content
AbbVie (ABBV) Stock Hits 52-Week High: More Room to Run?
Jun 19 / Zacks.com - Paid Partner Content
Sanofi/Regeneron's Kevzara Gets Marketing Approval in EU
10:18am / Zacks.com - Paid Partner Content
Novartis (NVS) Announced Positive Data on Psoriasis Cosentyx
Jun 15 / Zacks.com - Paid Partner Content
What Apple, Microsoft and Some of the World's Biggest Tech Companies Are Doing Now in...
Jun 24 / TheStreet.com - Paid Partner Content
Biotech Stock Roundup: Management Changes at Biogen, Alexion, GILD Files HIV Drug
Jun 15 / Zacks.com - Paid Partner Content
Samsung Could Sell More Drugs
Jun 23 / TheStreet.com - Paid Partner Content
Big US pharma dealmaking plunges to five-year low
Jun 12 / FT.com - Paid Partner Content
Dems Roast Trump for Leaving Medicare Out of Drug Price Order
Jun 21 / TheStreet.com - Paid Partner Content